RecruitingNCT04090034

Peptide Receptor Radionuclide Therapy (PRRT) for the Treatment of Neuroendocrine Tumors

Peptide Receptor Radionuclide Therapy (PRRT) for the Treatment of Neuroendocrine

Sponsor

Methodist Health System

Enrollment

50 participants

Start Date

Mar 28, 2024

Study Type

OBSERVATIONAL

Conditions

Neuroendocrine Tumors Gastroenteropancreatic Neuroendocrine Tumor

Summary

The specific aim is of this study is to gain a better understanding of the patient characteristics, treatment responses, survival outcomes, and adverse events associated with PRRT in patients with gastroenteropancreatic primary NETs.

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a procedure called Peptide Receptor Radionuclide Therapy for people with gastroenteropancreatic neuroendocrine tumor and neuroendocrine tumors. The study is currently recruiting participants at 2 locations. People eligible for this study include aged 18 Years and older.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.